Table 2 Copy number aberrations detected by CGH in FL and transformed DLBCL

From: Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma

Tumor no.

Diagnosis

Bcl-2 (%)

Number

CGH alterations Regions involved

 1

FLIII

NA

0

 2

FLI

75

0

 3

DLBCL

NA

0

 4

DLBCL

NA

2

−8p22-pter,−9p23-pter

 5

DLBCL

NA

3

+Xp11.3–q26,−8p22-pter,−9p22-pter

 6

DLBCL

0

3

+4,+6pter-q14,+12pter-q22

 7

DLBCL

NA

3

−5p,+7,−11q22–25

 8

DLBCL

0

4

−4q10–22,−6q14–21,+12pter-q22,+18q

 9

DLBCL

NA

6

−Xpter-q13,+3q26-qter,−4p16,−6q16-qter,+11q13–22,−15

10

DLBCL

NA

7

+1q31-qter,−2p23-pter,−4q13–21,−8p12-pter,+11q22–23,+12p11–q21,−18q22-qter

11

DLBCL

100

9

+2p14–16,+2q21–32,−3p14–21,−3q13–22,+6p,+7pter–q22,+8,−18q22–23,+21

12:1

DLBCL

NA

5

−X,+1q,−4p,+6p,−6q23-qter

12:2

DLBCL

NA

4

−X,+1q,+6p,−6q23-qter

13:1

DLBCL

80

11

−1p,−2q33-qter,−4pter-q21,−6p21–q21,+7,+10p12-pter,−10q23-qter,−11q,+12p12–q21,+14q12–21,+21q

13:2

DLBCL

80

10

+X,−1p32-pter,+7,+10p12-pter,−10q23-qter,−11q,+12p12–q21,+14q12–21,+21q,−22q

14:1

DLBCL

NA

8

+X,−1p21-pter,−6q,+7,−10q22–23,−15q,−16p,−17p

14:2

DLBCL

NA

12

+X,−1p21-pter,−3q13.1–21,−6q,+7,−10q22–23,−15q,−16p,−17,−18pter-q21,+19p,+21q

14:3

DLBCL

NA

12

+X,−1p21-pter,−3q13.1–21,−6q,+7,−10q22–23,−15q,−16p,−17,−18pter-q21,+19p,+21q

15:1

FLI

80

2

+X,−9p12–21

15:2

DLBCL

0

5

+4q31-qter,−9q22,+11q14–22,+13q12–22,+18q12–22

16:1

FLNA

50

0

16:2

DLBCL

NA

8

+Xq,−1p32-pter,−4q21-qter,−8p,+8q21-qter,+9q22-qter,−15,−17p

17:1

FLII

50

2

+X,+5p

17:2

DLBCL

0

4

+X,+5p,+12q10–21,−16q21–23

18:1

FLI

NA

0

18:2

DLBCL

NA

9

+2q22–33,+4q,−6p21,+6q10–21,+8q12–24,+9p,−11q12–13,+12q15–22,+12p12

19:1

FLII

NA

3

+12q11–21,−17p,+18pter-q21

19:2

DLBCL

100

4

−6q15–23,+11,−17p,+18pter-q21

20:1

FLI

50

3

+12q23–24,+17,+19

20:2

DLBCL

50

3

+12q23–24,+17,+19

21:1

FLI

50

1

+1q

21:2

DLBCL

50

2

+1q,+7

22:1

FLI

90

2

+12q13–15,+18q21

22:2

DLBCL

75

4

−8p,+12q13–15,+18q21,−19pter-13.2

23:1

FLI

100

1

+18p

23:2

DLBCL

NA

1

−4q

24:1

FLIII

NA

3

+1q23–32,−6q24–26,+18

24:2

DLBCL

NA

2

+Xq21-qter,+11p

25:1

FLI

NA

4

+1q,+11,+18q,+21q

25:2

DLBCL

80

4

+X,+11,+18q,+21q

26:1

FLI

NA

6

−9p,+9q22-qter,−12p,−13,−17p,+18

26:2

DLBCL

75

7

−1p21–32,−9p,+9q22-qter,−12p,−13,−17p,−19p

27:1

FLI

NA

0

27:2

DLBCL

25

2

+8p,+8q21.3-qter

27:3

DLBCL

NA

5

+X,+9pter-31,+15,+18pter-21,+19q13.2-qter

28:1

FLI

90

3

+X,−6q13–15; 22–23

28:2

DLBCL

100

5

+Xq25-qter,+2p14–16,−6q13–15; 22–23,+7

28:3

DLBCL

80

5

+X,+2p14–16,−6q13–15; 22–23,+7

29:1

FLI

50

6

+4,−12q23–24,+13q21–31,−16p,−17,+18

29:2

FLI

75

5

+4,−12q23–24,+13q21–31,−16p,+18

29:3

FLII

0

5

+2p13–21,+11p,+15q11–14,−15q15-qter,+19

29:4

DLBCL

25

12

−X +2p13–21,+3q25-qter,−4q32–33,−6q14–25,+7pter-q31,+8q10–22,+10p,−13q22-qter,+15q11–14,−15q15-qter,−17p,

30:1

FLII

NA

0

30:2

FLII

NA

0

30:3

FLII

80

2

+X,+1q

30:4

FLI

NA

2

+X,+1q

30:5

DLBCL

50

4

+X,+1q,−6q,+17q

30:6

DLBCL

NA

5

+X,+1q,−6q,+12,+17q

  1. I–III, grading concerning FL; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NA, not available. Bold style indicates high-level amplification.